Background and Objectives: Korean and traditional Chinese medicine state that pyrite is effective for fracture treatment, but supporting clinical data are limited. This systematic review aimed to investigate the therapeutic role of Chinese patent medicine containing pyrite (CPMP) in clinical treatment for fractures.
Materials and Methods: Seven electronic databases were searched using the keywords “pyrite”, “pyritum”, and “zirantong” between inception and December 2022, yielding 29 published clinical studies. Randomized controlled trials that included CPMP were considered eligible regardless of the fracture type. Quality assessment and meta-analysis of the included RCTs were also performed.
Results: Most studies showed high heterogeneity (I
2 > 50%) and significant results (
p < 0.05). Compared to the results of the control group, CPMP was more effective in terms of the primary outcome related to the efficacy rate, including the total effective rate, callus growth rate, bone union, and edema disappearance time (all
p < 0.00001) and in terms of secondary outcomes related to pain reduction, namely pain intensity and pain disappearance time, than the control group (both
p < 0.01). CPMP was more effective than the control group in terms of erythrocyte sedimentation rate (
p < 0.01), hematocrit (
p < 0.01), erythrocyte aggregation (
p < 0.05), and plasma viscosity (
p < 0.05). CPMP did not cause serious side effects, and the incidence of complications was significantly less than that in the control group.
Conclusions: CPMP may be a safe and effective alternative treatment for fractures and may be beneficial in preventing postoperative complications, reducing pain, relieving symptoms, and accelerating healing.
Full article
